Our findings from the R11 MASLD discovery cohort identified three significant proteins—NCAN, EPHA2, and APOE—whose genetically predicted plasma levels were associated with MASLD risk. Here, NCAN is linked to metabolic dysfunction-associated steatotic liver disease.